Factory High 99% Purity Ceritinib Powder CAS 1032900-25-6 Ceritinib

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: A31
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Adult
• State: Powder
• Purity: >99%
• Name: Ceritinib
• Appearance: White Powder
• Assay: 99%
• CAS: 1032900-25-6
• OEM: Available
• Sample: Available
• Suitable: Adult
• Function: Oncology Treatment
• Transport Package: Foil Bag
• Specification: 99
• Trademark: /
• Origin: China
• Production Capacity: 10000 Kgs Per Month

Product Description

Product Name	Ceritinib
Appearance	White Powder
CAS No.	1032900-25-6
MF	C28H36ClN5O3S

Ceritinib is a drug for the treatment of lung cancer. It is an ALK inhibitor. It was approved in April 2014 by the Food and Drug Administration for the treatment of ALK-positive metastatic non-small cell lung cancer (NSCLC) following treatment with crizotinib.

 

1. Oncology Treatment: Ceritinib powder is primarily used in the treatment of advanced non-small cell lung cancer (NSCLC) that harbors a mutation in the anaplastic lymphoma kinase (ALK) gene.

2. Targeted Therapy: As a targeted therapy, it specifically inhibits the ALK protein, blocking its signaling pathways involved in cancer cell growth and proliferation.

3. Second-Line or Later Treatment: It is often prescribed as a second-line or subsequent therapy option for patients who have progressed after receiving crizotinib, another ALK inhibitor.

4. Combination Therapy: Research is ongoing to explore the potential of combining ceritinib with other therapies to enhance treatment outcomes.

1. Inhibits ALK Kinase Activity: Ceritinib functions by selectively inhibiting the activity of the ALK tyrosine kinase, preventing its abnormal signaling that drives tumor growth and survival.

2. Tumor Growth Suppression: By disrupting ALK-mediated signaling, ceritinib helps to slow or halt the growth of ALK-positive cancer cells.

3. Prolongs Survival: In clinical trials, ceritinib has demonstrated the ability to improve progression-free survival and overall survival in patients with ALK-positive NSCLC.

4. Reduces Tumor Burden: Its targeted mechanism of action contributes to reducing the burden of cancer in the body, potentially improving patients' quality of life.

5. Minimizes Off-Target Effects: As a relatively selective inhibitor, ceritinib aims to minimize adverse effects on non-cancerous cells, although some side effects may still occur.